Application of ITA as TET2 inhibition factor in preparation of nasopharyngeal carcinoma cell immune escape inhibition drug
Through ITA as a TET2 inhibitor, it interferes with the immune escape mechanism of nasopharyngeal carcinoma cells, inhibits TET2 demethylation and M2 macrophage polarization, solves the problem of TAMs-mediated immunosuppression in nasopharyngeal carcinoma and realizes tumor growth The slowdown and recovery of immune response provide scientific basis for targeted treatment of ITA metabolic pathways.
Patent Information
- Application Number
- CN202411176955.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
AI Technical Summary
The mechanism of tumor immune escape in nasopharyngeal carcinoma has not been fully understood, especially the mechanism of TAMs-mediated immunosuppression, and the role of ITA in nasopharyngeal carcinoma has not been fully studied, resulting in limited existing treatment strategies.
Through ITA as a TET2 inhibitor, it inhibits TET2 demethylation function, reduces 5hmC levels, promotes polarization of M2 macrophages, regulates the function of TAMs, inhibits the killing ability of CD8+ T cells, and interferes with ITA metabolic pathways to inhibit nasopharyngeal Proliferation, migration and invasion of cancer cells.
Effectively inhibit the immune escape of nasopharyngeal carcinoma cells, restore CD8+ T cell activity, enhance anti-tumor immune response, provide new therapeutic strategies, significantly slow down tumor growth, and provide scientific basis for targeted treatment of ITA and its metabolic pathways .
Smart Images

Figure CN119055626A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug development and treatment of tumor immune escape inhibition, and in particular to the use of ITA as a TET2 inhibitor in the preparation of nasopharyngeal carcinoma cell immune escape inhibitors. Background Art
[0002] Nasopharyngeal carcinoma (NPC) is a group of malignant tumors that originate from the epithelial cells of the nasopharyngeal mucosa and are highly invasive and metastatic. According to statistics, there are more than 130,000 newly diagnosed cases of NPC each year worldwide, and about 70% of patients are already in the advanced stage and have distant metastasis when they are first diagnosed, posing a great threat to human health. The tumor microenvironment (TME) provides conditions for the occurrence and growth of tumors, and is also the place where the body's immune system competes with tumors. TME can produce immunosuppressive effects by inhibiting T cell anti-tumor immunity, prompting tumor cell immune escape, thereby leading to tumor metastasis.
[0003] Tumor-associated macrophages TAMs (TAMs) are the most numerous immune cells in the TME and play a key regulatory role in the malignant progression of tumors.
[0004] The tumor-regulatory effects of TAMs rely on their heterogeneity. For one, M1 TAMs amplify the immune response by secreting pro-inflammatory factors, thereby exerting a tumor-suppressive effect. M2 TAMs, on the other hand, mainly mediate immunosuppression by secreting anti-inflammatory factors, thereby exerting a tumor-promoting effect. In addition, TAMs can secrete various types of immunosuppressive enzymes to inhibit the immune response of cytotoxic T lymphocytes (CTLs). Therefore, intervening in TAM-mediated immunosuppression is a potential therapeutic strategy against tumor metastasis, but the exact mechanism of TAM-mediated immunosuppression is still unclear.
[0005] Itaconate (ITA) is an important effector molecule in the endogenous immune system, and the immune response gene 1 (IRG1) protein links metabolism with immunity by catalyzing the production of ITA. ITA is synthesized and secreted in response to stress. The synthesized ITA exerts anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines, and thus may play an immunosuppressive role. Zhao et al. found that IRG1-mediated The production of ITA in the mitochondria has a tumor-promoting effect. In addition, IRG1-induced ITA depletes CD8 + T cells promote tumorigenesis. Currently, few studies have investigated the role of ITA in NPC and its related mechanisms.
[0006] In view of the existing problems, the present invention proves that NPC cells promote M2 type Polarization and ITA production. In addition, TAMs promote the proliferation, migration and invasion of NPC cells through IRG1-catalyzed ITA production. In addition, IRG1-catalyzed ITA production promotes the M2 polarization of TAMs and reduces CD8 + Importantly, the promotion of ITA on NPC depends on immunosuppression. Therefore, the present invention supports that targeting the metabolic pathway that produces ITA may be a potential strategy for treating NPC. Summary of the invention
[0007] The purpose of the present invention is to provide the use of ITA as a TET2 inhibitor in the preparation of nasopharyngeal carcinoma cell immune escape inhibitors. ITA released by TAM enhances the immune escape of nasopharyngeal carcinoma cells by targeting TET2, thereby promoting the progression of nasopharyngeal carcinoma, suggesting that interfering with the metabolic pathway of ITA is a new strategy for the treatment of nasopharyngeal carcinoma.
[0008] In order to achieve the above technical objectives and the above technical effects, the present invention is implemented through the following technical solutions:
[0009] Application of ITA as a TET2 inhibitor in the preparation of nasopharyngeal carcinoma cell immune escape inhibitors.
[0010] An inhibitor for inhibiting immune escape of nasopharyngeal carcinoma (NPC) cells, comprising itaconic acid (ITA) and a pharmaceutically acceptable salt thereof that effectively inhibits TET2 activity.
[0011] Furthermore, the inhibitor is a substance that inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells.
[0012] Specifically, it reduces the intracellular 5-hydroxymethylcytosine (5hmC) level by inhibiting the demethylation function of TET2; promotes the polarization of M2 macrophages; regulates the M2 polarization of TAMs and affects their phagocytic function by inhibiting the expression of IRG1; inhibits the killing ability of CD8+T cells against HK-1 and HNE2 cells, and reduces the release of INF-γ.
[0013] Furthermore, the inhibitor has an in vitro action concentration of 125 μM and an in vitro action time of 24 h.
[0014] Furthermore, the in vivo administration dosage of the inhibitor is 50 mg / kg.
[0015] Beneficial effects of the present invention:
[0016] The present invention first reveals the role of TAM in promoting immune escape in the microenvironment of nasopharyngeal carcinoma, especially the polarization process of M2 TAM. Through flow cytometry and immunofluorescence staining and other techniques, the phenotypic analysis of TAM in the tumor microenvironment was carried out, and it was found that nasopharyngeal carcinoma cells significantly increased the proportion of M2 cells in TAM by secreting a variety of pro-inflammatory factors (such as IL-6, IL-10, etc.). This polarization enables TAM to secrete a variety of immunosuppressive factors, such as itaconic acid (ITA), thereby inhibiting CD8 + The activity and proliferation of T cells were enhanced, reducing their cytotoxicity. In the subsequent ELISA and qRT-PCR experiments, it was further confirmed that the secretion level of ITA was positively correlated with the ratio of M2 TAMs, clarifying the role of TAMs as key regulators in tumor immune escape. This discovery provides a new perspective on the interaction of immune cells in the tumor microenvironment.
[0017] The present invention deeply explores how ITA enhances the immune escape ability of tumor cells by regulating the expression of TET2. In in vitro experiments, Western blot technology showed that ITA significantly reduced the protein expression of TET2 in nasopharyngeal carcinoma cells, and combined with RNA interference (siRNA) technology, the inhibitory effect of ITA on TET2 was further confirmed by knocking down the expression of TET2. TET2 is an important tumor suppressor, and its functional loss is closely related to the occurrence of various tumors. Through fluorescent quantitative PCR and methylation feature analysis, it was found that the downregulation of TET2 affected the expression of related tumor suppressor genes, prompting tumor cells to show higher proliferation and invasiveness. The elucidation of this mechanism reveals the important role of ITA in the immune escape of nasopharyngeal carcinoma cells and emphasizes the potential value of restoring host immunity by regulating TET2 expression.
[0018] This paper proposes intervention measures for the ITA metabolic pathway, demonstrating its potential for application in the treatment of nasopharyngeal carcinoma. The experiment used a mouse PDX model to evaluate the effect of ITA on tumor progression in a real tumor microenvironment. By inhibiting the synthesis of ITA with medication, it was observed that tumor growth was significantly slowed, accompanied by CD8 + The increase in the number of T cells and the restoration of their activity. Flow cytometry analysis showed that the proportion of cytotoxic T cells in the T cell population after ITA inhibition increased significantly, indicating that ITA inhibition has a significant promoting effect on immune cell responses. In addition, combined with mass spectrometry analysis, it was found that inhibiting ITA synthesis also affected the functional state of TAMs, reducing their M2 polarization level, thereby further enhancing the anti-tumor immune response. This achievement provides a scientific basis for the targeted treatment of ITA and its related metabolic pathways, and opens up new clinical treatment strategies.
[0019] The results of the present invention provide an important framework for the combination of basic research and clinical transformation. By revealing the mechanism of action of ITA in the immune escape of nasopharyngeal carcinoma, the study lays the foundation for the development of related targeted drugs. At the same time, combined with bioinformatics methods, the expression patterns of ITA and TET2 in tumor samples were analyzed, and it was found that their performance in different tumor patients had a certain correlation. This evidence not only verifies the potential of ITA as a biomarker, but also points out the direction for subsequent clinical trials and promotes the progress of immunotherapy for nasopharyngeal carcinoma. Through this series of studies, the importance of basic biological research and its application potential in the transformation of tumor treatment are emphasized, providing new ideas for the personalized treatment of tumors.
[0020] Of course, any product implementing the present invention does not necessarily need to achieve all of the advantages described above at the same time. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for describing the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative work.
[0022] Figure 1 Nasopharyngeal carcinoma cell stimulation The m2 polarization promotes the ITA from Release. (A) Schematic diagram of monocyte and co-culture system. (B) Flow cytometry was used to detect the proportion of M2 polarized cells in the control group (THP-1 monocyte monoculture), M2 stimulation group (THP-1 monocytes stimulated by IL-4 plus IL-13), NEC co-culture group (THP-1 monocytes co-cultured with NEC), and NPC co-culture group (THP-1 monocytes co-cultured with HK-1 cells). (C) Protein levels of Arg-1 and CD206 in THP-1 monocytes in the above-mentioned different culture systems. (DF) ELISA detection of tam-related cytokines (IL-6, IL-10 and VEGF) in the cell supernatants of different THP-1 monocyte culture systems. (G) Gas chromatography-mass spectrometry was used to detect the concentration of ITA in the cell supernatants of different THP-1 monocyte culture systems. Data are expressed as mean ± SEM, and one-way analysis of variance was performed;
[0023] Figure 2 TAMs affect the malignant phenotype of HK-1 cells by regulating IRG1-mediated ITA production. (AF) m2 type In vitro simulation of TAM model. (A and B) The knockdown effect of si-IRG1#1, si-IRG2#2 and si-IRG1#3 on IRG1 in THP-1 monocytes was verified by RT-qPCR and western blot. Data are presented as mean ± SEM and analyzed by one-way ANOVA (***P<0.001, **P<0.01, *P<0.05vs.si-NC; no, not significant). (C-D) Viability, colony formation, wound healing and transwell invasion assays of NPC cells in control (HK-1 cells stimulated with PBS), ITA (HK-1 cells stimulated with ITA), TAM-si-NC (HK-1 cells co-cultured with TAM-si-NC and stimulated with PBS), TAM-si-IRG1 (HK-1 cells co-cultured with TAM-si-IRG1 and stimulated with PBS), and TAM-si-IRG1+ITA (HK-1 cells co-cultured with TAM-si-IRG1 and stimulated with ITA) groups. Data are expressed as mean ± SEM and analyzed by one-way ANOVA;
[0024] Figure 3 IRG1-mediated ITA inhibition inhibits TAM phagocytosis. (A) Flow cytometry analysis of control (M0 type CD206 in TAM-si-NC (pbs-treated HK-1 cells co-cultured with TAM-si-NC), TAM-si-IRG1 (pbs-treated HK-1 cells co-cultured with TAM-si-IRG1), and TAM-siIRG1+ITA (ITA-treated HK-1 cells co-cultured with TAM-si-IRG1) + (BD) ELISA was used to detect the levels of IL-6, IL-10 and VEGF released by TAM. (E) Flow cytometry was used to detect the phagocytic effect of treated TAM on HK-1 cells. (F) Flow cytometry analysis of the control group (M0- ), TAM-si-NC (HNE2 cells co-cultured with TAM-si-NC+PBS), TAM-siIRG1 (HNE2 cells co-cultured with TAM-si-IRG1+PBS) and TAM-si-IRG1+ITA (HNE2 cells co-cultured with TAM-si-IRG1+ITA) CD206 + TAM percentage. (GI) Determination of IL-6, IL-10, and VEGF levels released by TAM. (J) Flow cytometry was used to determine the phagocytic capacity of the treated TAM. Data are expressed as mean ± SEM and analyzed by one-way ANOVA;
[0025] Figure 4 IRG1-mediated ITA inhibits CD8+ Killing of T cells. (A) Flow cytometry analysis of apoptosis of HK-1 cells presented by siinfkl in control (HK-1 cells treated with PBS), ITA (HK-1 cells stimulated with ITA), TAM-si-NC (HK-1 cells treated with PBS co-cultured with TAM-si-NC), TAM-si-IRG1 (HK-1 cells treated with PBS co-cultured with TAM-si-IRG1), and TAM-si-IRG1+ITA (HK-1 cells stimulated with ITA co-cultured with TAM-si-IRG1) groups. (B) The percentage of cleaved siinfkl-presenting HK-1 cells carrying the luciferase gene was evaluated based on fluorescence intensity. (C) ELISA detection of CD8 + (D) Flow cytometric analysis of siINFEKL-expressing HNE2 cells and CD8 + T cell co-cultures were control group (PBS stimulated HNE2 cells), ITA (ITA stimulated HNE2 cells), TAM-si-NC (PBS treated HNE2 cells co-cultured with TAM-si-NC), TAM-si-IRG1 (PBS treated HNE2 cells co-cultured with TAM-si-IRG1) and TAM-si-IRG1+ITA (ITA treated HNE2 cells co-cultured with TAM-si-IRG1). (E) The percentage of lysed HNE2 cells containing the luciferase gene was evaluated by analyzing the fluorescence intensity. (F) CD8 + The level of INF-γ released by T cells. Data are expressed as mean ± SEM and analyzed by one-way ANOVA;
[0026] Figure 5 ITA promotes subcutaneous xenograft tumor growth by mediating immune escape. (A) Schematic diagram of animal experiment (CD34 + (B) Subcutaneous xenograft tumor growth curve. (C) Photograph of subcutaneous tumor. (D) Subcutaneous xenograft tumor and IF analysis of infiltration rate. (E) Immunohistochemical evaluation of CD8 expression in subcutaneous xenograft tumors. Data are expressed as mean ± SEM, and one-way ANOVA was used;
[0027] Figure 6 In nude mice lacking the immune system, the tumor-promoting effect of ITA is weakened. (A) Tumor growth in BALB / c nude mice carrying HK-1 cells (n=6). (B) Growth curve of subcutaneous nasopharyngeal carcinoma tumor. (C) Typical in vivo imaging images of animals. Data are expressed as mean ± SEM and analyzed by unpaired t test;
[0028] Figure 7 ITA exerts tumor immunosuppression by interacting with TET2. (A) Dot blot images show that different concentrations of ITA treated m0 type 5hmC level. (B and C) Verification of the interference efficiency of si-TET2#1, si-TET2#2 and si-TET2#3 on TET2 in THP-1 monocytes. (D) CD206 in the control group (pbs-treated HK-1 cells co-cultured with TAM-si-NC), ITA group (ITA-treated HK-1 cells co-cultured with TAM-si-NC), si-TET2 group (pbs-treated HK-1 cells co-cultured with TAM-si-TET2) and si-TET2+ITA group (ITA-treated HK-1 cells co-cultured with TAM-si-TET2) + The percentage of tam was determined. (EG) Analysis of IL-6, IL-10, and VEGF levels released by tam in each group. (H) Flow cytometry was used to detect the phagocytic effect of tam. (1) CD8 + The effect of T cells on HK-1 cell apoptosis. (J) CD8 + Killing effect of T cells. (K)CD8 + T cells release INF-γ. Data are expressed as mean ± SEM and analyzed by one-way ANOVA (***P<0.001, **P<0.01, *P<0.05);
[0029] Figure 8 Schematic diagram of how tumor-associated macrophage-derived itaconate promotes immune escape via TET2, thereby promoting nasopharyngeal carcinoma progression;
[0030] Nasopharyngeal carcinoma cells promote M2 polarization of TAMs and IRG1-mediated ITA release, which in turn attenuates CD8 + The killing effect of T cells reduces the phagocytic effect of TAMs, thereby promoting the proliferation, migration and invasion of nasopharyngeal carcinoma cells. DETAILED DESCRIPTION
[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Example 1
[0033] The use of ITA described in this example as a TET2 inhibitor in the preparation of an inhibitor of nasopharyngeal carcinoma cell immune escape.
[0034] The present embodiment provides an inhibitor for inhibiting immune escape of nasopharyngeal carcinoma (NPC) cells, wherein the inhibitor includes itaconic acid (ITA) and a pharmaceutically acceptable salt thereof that effectively inhibits TET2 activity.
[0035] In this embodiment, the inhibitor is a substance that inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells.
[0036] Specifically, it reduces the intracellular 5-hydroxymethylcytosine (5hmC) level by inhibiting the demethylation function of TET2; promotes the polarization of M2 macrophages; regulates the M2 polarization of TAMs and affects their phagocytic function by inhibiting the expression of IRG1; inhibits the killing ability of CD8+T cells against HK-1 and HNE2 cells, and reduces the release of INF-γ.
[0037] In this example, the inhibitor has an in vitro action concentration of 125 μM and an in vitro action time of 24 h.
[0038] In this example, the in vivo administration dose of the inhibitor is 50 mg / kg.
[0039] Example 2
[0040] Methods and Materials
[0041] Cell culture
[0042] Human nasopharyngeal epithelial cells (Catalog No. CL-0804; Pricella, Wuhan, China) were cultured in cell-specific medium (Catalog No. CM-0804; Pricella). Human NPC cell lines HNE2 (Catalog No. IM-H434; Immocell, Xiamen, China) and HK-1 (Catalog No. CC0708 Cellcook, Guangzhou, China) were cultured in DMEM (Thermo, Waltham, MA, USA) or RPMI-1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, Thermo) and 1% penicillin (P / S, Pricella), respectively. Human THP-1 monocytes (Catalog No. CL0233 Pricella) were cultured in RPMI-1640 supplemented with 10% FBS, 0.05 mm β-mercaptoethanol (Sigma) and 1% P / S. All cells were cultured in a 37°C incubator (Thermo) with a 5% CO2 environment.
[0043] polarization
[0044] To induce M0 About 1×10 6 THP-1 monocytes were cultured for 6 hours. To induce M2 polarization, THP-1 monocyte-derived M0 polarization was performed. The cells were stimulated with IL-4 (20 ng / mL, Sigma) and IL-13 (20 ng / mL, Sigma) for 48 hours.
[0045] Cell transfection
[0046] THP-1 monocytes were transfected with different small interfering RNA (siRNA) (si-NC, si-IRG1#1, si-IRG1#2, si-IRG1#3, si-TET2#1, si-TET2#2 or siTET2#3) (GenePharma, Shanghai, China) in Opti-MEM serum-free medium using HiPerFect transfection reagent (Qiagen, Hilden, Germany). Transfected cells were cultured in appropriate culture medium for 24 hours.
[0047] Cell co-culture
[0048] To analyze the HK-1 cells' response to M0 Towards M2 type The experiment was divided into the following 4 groups: control (single culture M0 type ), M2 stimulation (monocultured M0 type stimulated with IL-4 and IL-13 ), NEC co-culture (M0 type co-cultured with NECs ) and NPC co-culture (M0 type co-cultured with HK-1 cells NPC cells or NECs and co-culture system.
[0049] To investigate whether IRG1-induced ITA production in TAMs mediates the malignant behavior of NPC cells, the experiment was divided into the following five groups: control group, ITA group, TAM-si-NC group, TAM-si-IRG1 group, and TAM-si-IRG1+ITA group. For the control group, NPC cells (approximately 1×10 4 NPC cells (about 1×10 / chamber) were seeded into the upper chamber and cultured with normal medium supplemented with PBS. 4TAM-si-NC and TAM-si-IRG1 groups were inoculated into the upper chamber and stimulated with ITA (125 μM). For the TAM-si-NC and TAM-si-IRG1 groups, the upper chamber was cultured as in the control group, but the lower chamber was cultured with TAM transfected with si-NC or si-IRG1. For the TAM-si-IRG1+ITA group, the upper chamber was cultured as in the ITA group, but the lower chamber was cultured as in the TAM-si-IRG1 group. The amount of PBS was the same as that of ITA.
[0050] In order to analyze the function of TET2, the M0 The NPC cells were divided into the following groups: control group, ITA group, si-TET2 group and si-TET2+ITA group. For the ITA group, ITA-stimulated NPC cells were co-cultured with M0-type For the si-TET2 group, NPC cells treated with PBS were co-cultured with M0 cells transfected with si-TET2. For the si-TET2+ITA group, ITA-stimulated NPC cells were co-cultured with si-TET2-transfected M0 cells. Co-culture
[0051] Flow cytometric analysis
[0052] The harvested Prepare a single cell suspension. After washing, follow the manufacturer's instructions. On ice and protected from light, staining with CD206APC (Cat. No. 141714, Biolegend, San Diego, California, USA) was performed. Flow cytometry analysis was performed on a BD FACSCanto II system (BD Biosciences, Frank, New Jersey, USA), and data were analyzed using FlowJo v10 software (FlowJo, Ashland, OR, USA).
[0053] Western blotting
[0054] Western blots were separated using RIPA buffer (Cat. No. P0013C, Beyotime, Shanghai, China), and equal amounts of total protein were separated and transferred to PVDF membranes using a BCA kit (Cat. No. 23227). The membrane was blocked with 5% skim milk and then incubated at 4°C with anti-CD206 (Cat. No. FNab09812, Fine Biotech Co., Ltd., Wuhan, China), Arg-1 (Cat. No. PA1783, Boster, Wuhan, China), IRG1 (Cat. No. 17805S, Cell Signaling Technology, USA), β-actin (Cat. No. FNab00869, Fine Biotech Co., Ltd.) and TET2 (Cat. No. orb537560, Biorbyt, Wuhan, China). After incubation with the secondary antibody, protein bands were detected using an ECL kit (Tanon, Shanghai, China).
[0055] Enzyme-linked immunosorbent assay (ELISA)
[0056] The levels of IL-6, IL-10 and VEGF in different culture media were assessed using the corresponding kits as described by the manufacturers. Table 1 shows the information of the kits used for this experiment.
[0057] Table 1 Information about the kit used for ELISA
[0058]
[0059] Gas chromatography-mass spectrometry (GC-MS)
[0060] ITA levels in cell culture supernatant samples were measured according to previous reports. Extracellular metabolites were extracted using ice-cold methanol / water plus internal standard mixture (5:1, v / v). For quantification, GC-MS measurements were performed in selected ion monitoring mode on an Agilent 7890AGC connected to an Agilent 5975C Inert XL mass selective detector (Agilent Technologies, Santa Clara, California, USA) using the following mass numbers: m / z 301.2; 343.2; 358.2 (retention time: 60 ms).
[0061] Reverse transcription-quantitative PCR (RT-qPCR)
[0062] Total RNA was extracted using Trizol (Cat. No. 15596-026, Ambion, Austin, Texas, USA). Total RNA (2 μg) was reverse transcribed using a prime script RT kit (Cat. No. RR047A, Takala, Dalian, China). qPCR reactions were performed using TB Green Premix Ex Taq II (Cat. No. RR820A, Takara).
[0063] Pass 2 -ΔΔCt Methods Relative mRNA levels were calculated. Table 2 provides the sequences of all primers.
[0064] Table 2 All primer sequences used in RT-qPCR
[0065]
[0066] Colony formation assay
[0067] NPC cells were co-cultured with TAMs for 14 days. They were fixed in 4% paraformaldehyde (Solarbio, Beijing, China), and then colonies were stained with 0.1% crystal violet (Solarbio). Images were taken and counted in every four fields of view under an Olympus BX51 microscope (Olympus, Tokyo, Japan).
[0068] Wound healing assay
[0069] NPC cells were plated in the upper compartment. After 24 hours, the cell-free area was scraped out using a micropipette tip (200L), serum-free medium was added, and the lower compartment was inoculated with TAMs. Wound closure was observed and photographed at 0 and 24 hours, and then analyzed using ImageJ software.
[0070] Transwell invasion assay
[0071] 100 μL of mat rigel (BD Biosciences) was added to the upper compartment and incubated at 37°C for 4 h. NPC cells (1×10 4 Cells were seeded in the upper compartment, and the upper compartment was seeded in TAMs. After 24 hours, the migrated cells were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. The cells were photographed with a microscope and counted with ImageJ.
[0072] T cell function assay
[0073] Using EasySep Mouse CD8 +CD8 T cell isolation kit (Cat. No. 19853, STEMCELL, USA) was used to generate CD8 T cells from the spleen of OT-I mice. + T cells were then stimulated for 2 days with anti-CD28 (5 mg / mL, catalog number BE0015-1, Bioxcell, Beijing, China) and anti-CD3 (0.5 mg / mL, catalog number BE0001-1, Bioxcell) pre-coated plates and maintained in RPMI-1640 with IL-2 (0.4 ng / mL, catalog number 402-ML-020, R&D Systems, Minnesota, USA) to expand T cells. SIINFEKL peptide (catalog number HY-P1489, MCE, USA) was overexpressed in NPC cells to serve as target cells.
[0074] In the T cell killing experiment, nasopharyngeal carcinoma cells expressing SIINFEKL and CD8 + T co-culture, CD8 + T cells were treated with different conditioned medium (CM) from the control group, ITA group, TAM-si-NC group, TAM-si-irg1 group, and TAM-si-irg1+ITA group, and allowed to adhere overnight. For apoptosis analysis, NPC cells were double-stained with Annexin V-FITC and propidium iodide. C1062L, Beyotime) staining was detected using a BD FACSCanto II system flow cytometer (BD Biosciences) according to the manufacturer's instructions.
[0075] To generate luciferase reporter cells, 293T cells were co-transfected with pHIV-luc-zsgreen (Catalog No. 39196, Addgene, Massachusetts, USA), psPAX2 (Catalog No. 12260, Addgene) and pMD2 g (Catalog No. 12259, Addgene) plasmids. After 72 hours, the lentivirus was collected and filtered (0.45mM filter). The lentivirus with pHIV-luc-zsgreen was used to infect NPC cells expressing siinfeklex. To analyze T cell killing, the culture medium was removed after the target cells were co-cultured with T cells, and D-luciferin (150mg / mL, Sigma) was added and incubated for 10 minutes. The measurement of luciferase activity was performed by FLUOstar OPTIMA microplate reader (BMG Laboratory, Germany). The calculation of T cell killing ability is as follows: cell lysis (%) = (value blank-value detection) / value blank.
[0076] To detect the interferon gamma (IFN-γ) level in the supernatant, ELISAMAX Standard Kit Mouse IFN-γ Kit (Catalog No.: MBS262163, MyBiosource Inc., California, USA) was used according to the protocol.
[0077] Phagocytosis
[0078] For phagocytosis analysis, cells from the control group, TAM-si-NC group, TAM-si-IRG1 group, and TAM-si-IRG1+ITA group were After 24 hours of culture, the cells were incubated with NPC cells labeled with MitoTracker Deep Red for 10 minutes. The monoculture of 100 μg / mL was established, and the other groups were consistent with the above co-culture. After washing, the cells were analyzed by flow cytometry. The fluorescent part was quantified.
[0079] Animal experiments
[0080] Animal Experiments All animal experiments were performed on 4-6 week old mice (Gem Pharmatech (Nanjing, China)), including huHSC-NCG (n=24) and BALB / c (n=12) mice. Mice were maintained under specific pathogen-free conditions with a 12-h light / dark cycle, room temperature of 23±2°C, and humidity of 30-70%. All procedures were approved by the Experimental Animal Welfare and Ethics Committee of the Third Xiangya Hospital of Central South University.
[0081] For subcutaneous xenograft experiments in huHSC-NCG mice, HK-1 cells (1×10 6 cells) were implanted into the right side of huHSC-NCG mice. 15 days after injection, huHSC-NCG mice were treated according to the following groups: control group (vehicle + isotype), ITA (ITA + isotype), anti-programmed cell death ligand-1 (PD-L1) (vehicle + anti-PD-L1) and ITA + anti-PD-L1 (n = 6 mice / group). Mice received intraperitoneal injections of vehicle / ITA and isotype / anti-PD-L1 treatments alternating every day. Mice were treated with 50 mg / kg ITA and PBS was used as a vehicle control. Isotype control (catalog number BE0089, Bioxcell) and anti-PDL1 (catalog number BE0146 l, biox cell) (100 μg / mouse) were performed. For the BALB / c mouse subcutaneous tumor xenograft model, HK-1 cells (1×10 6100 cells) were implanted into the right flank of the mice (n=6 mice / group). 15 days after injection, mice were treated according to the following groups: control group (vehicle) and ITA. Starting from day 12, tumor size was measured every 4 days. The volume was estimated according to the formula 1 / 2×(length×width2). 50 days after cell inoculation, all mice were sacrificed and tumor tissues were collected for further analysis.
[0082] Immunofluorescence analysis
[0083] Tissue samples were blocked with 5% bovine serum albumin for 30 minutes at room temperature and then incubated with the primary antibody overnight at 4°C. The fluorescently coupled secondary antibody was then incubated for 1 hour in the dark at room temperature. Primary antibodies included anti-F4 / 80 (Catalog No. FNab02922, Fine Biotech Co., Ltd.) and anti-CD163 (Catalog No. A72933, EpiGentek, USA) antibodies. DAPI (Beyotime) was used to visualize the nucleus. Confocal microscopy (LSM710, Zeiss, Jena, Germany) was used for the acquisition of fluorescent images.
[0084] Immunohistochemistry (IHC)
[0085] Paraffin-embedded slides were dewaxed, rehydrated, and then subjected to antigen retrieval. Endogenous peroxidase was then performed using a 3% H2O2 solution. After blocking with 10% goat serum, the tissues were incubated overnight at 4°C with the primary antibody against CD8 (Catalog No. LS-C414175, LSBio, USA). After incubation with a biotin-conjugated secondary antibody, immunoreactive proteins were detected by 3,3'-diaminobenzidine staining. Images of representative areas were taken using a microscope.
[0086] Dot blot analysis
[0087] M0 type The cells were treated with low, medium and high concentrations of ITA. Genomic DNA was extracted from the collected cells using a genomic DNA purification kit (Catalog No. K0512, Thermo). The extracted DNA (1 μg) was mixed with 6×SSC (200 μL) and then denatured at 100°C for 10 minutes. The spots were transferred to a nitrocellulose membrane and dried. The level of 5hmC (Catalog No. 39769, Active Motif, Carlsbad, CA) was analyzed using standard Western blot analysis.
[0088] Statistical analysis
[0089] Statistical analysis was performed using GraphPadPrism software. In general, comparisons between two groups were performed using a two-tailed t-test, and multiple comparisons were performed using one-way analysis of variance with Tukey's post hoc test. Data from at least three independent experiments were expressed as standard error of the mean (SEM). P < 0.05 was considered statistically significant.
[0090] Example 3
[0091] The experiment described in Example 2 was carried out based on Example 1, and the results were as follows:
[0092] NPC cells induce M2 type Polarize and promote Cellular release of ITA
[0093] In order to explore the interaction between NPC cells and TAM, this example Co-cultured with NPC cells for 48 hours. It is induced by stimulating THP-1 monocytes with IL-4 plus IL-13, such as Figure 1 As shown in A and B. Interestingly, compared with THP-1 monocytes in monoculture, CD206 + The number of cells increased significantly, but these changes were not observed in THP-1 monocytes co-cultured with NEC cells ( Figure 1 A and B). As expected, the protein levels of the M2 markers Arg-1 and CD206 were significantly increased after stimulation with IL-4 plus IL-13 or co-culture with NPC cells, and IL-4 plus IL-13 stimulation resulted in higher protein levels of Arg-1 and CD206 than co-culture with NPC cells ( Figure 1 C). Similarly, levels of cytokines IL-6, IL-10, and VEGF were higher in supernatants derived from THP-1 monocytes stimulated with IL-4 plus IL-13 or co-cultured with NPC cells than in monocultured THP-1 monocytes ( Figure 1 DF). Because the activated The unique small molecule metabolite ITA was produced, which has the effect of promoting tumor growth. The concentration of ITA in the cell supernatant was measured by GCMS. The results showed that compared with monocultured THP-1 monocytes, IL-4 plus IL-13 stimulation and co-culture with NPC cells caused a significant increase in ITA concentration. In summary, these results indicate that NPC cells induce the M2 type polarization, and helps from ITA release in cells
[0094] TAMs promote the malignant behavior of NPC cells by regulating IRG1-mediated ITA levels
[0095] Since TAMs and M2 The M2 type has significant phenotypic and functional similarities and is immunosuppressive specific It is often used as a model to study the role of TAMs. Researchers have shown that ACOD1 encoded by IRG 1 catalyzes the production of ITA. Therefore, we further investigated whether IRG1-mediated ITA production in TAMs affects the malignant behavior of HK-1 cells. The importance of IRG1-mediated ITA production in TAMs was discussed by loss-of-function strategy. Figure 2 As shown in A and B, the knockdown efficiency of each siRNA was verified by RT-qPCR and western blot. Note that si-IRG1#2 with the best knockdown efficiency was used for subsequent functional verification. It was found that both ITA and TAMs increased the viability of HK-1 cells and contributed to the colony formation, migration and invasion of HK-1 cells, and these effects mediated by TAMs were weakened after IRG1 knockout. Importantly, ITA partially overturned the inhibitory effects of IRG 1 knockout TAMs on HK-1 cell proliferation, migration and invasion ( Figure 2 CF).
[0096] For further verification, the above experiments were performed with the NPC cell line HNE2. The same results were observed in HNE2 cells, that is, TAMs promoted the colony formation, migration and invasion of HNE2 cells by regulating IRG1-mediated ITA production (Supplementary Figure 1 AC). Taken together, these results suggest that TAMs regulate IRG1-mediated ITA production to influence the malignant behavior of NPC cells.
[0097] IRG1-mediated ITA regulates M2 polarization and phagocytosis of TAMs
[0098] Subsequently, co-cultured M0 and HK-1 cells to analyze the effect of ITA on the M2 polarization of TAMs. + For TAMs, CD206 + The percentage of TAMs was higher than that in the control group (M0 type), but IRG1 silencing reduced CD206 + In addition, after ITA supplementation, IRG1 silencing mediated the expression of CD206 + The decline in TAMs percentage was overturned ( Figure 3A). In addition, after co-culture with HK-1 cells, the levels of IL-6, IL-10, and VEGF released by TAMs were significantly increased. Under the same culture conditions, knockdown of IRG1 in TAMs reversed the increase in the levels of the above cytokines, while the effects mediated by IRG1 inhibition were abolished after the addition of ITA ( Figure 3 BD). Next, this example analyzed the phagocytic function of TAMs. The treated TAMs were co-cultured with fresh HK-1 cells labeled with MitoTracker Deep Red. Flow cytometry results showed that the phagocytic function of TAMs was inhibited after co-culture with HK-1 cells, but the above inhibitory phagocytic function was restored after IRG1 knockout. As expected, after adding ITA, the effect of IRG1 knockdown-mediated improvement in TAMs phagocytosis was negligible ( Figure 3 E) The above results on the effect of ITA on the M2 polarization and phagocytic ability of TAMs were then followed by It was confirmed by co-culture with HNE2 cells. Consistently, it was observed that the IRG1 knockout-mediated inhibition of M2 polarization and the promotion of TAMs phagocytosis were restored after the addition of ITA ( Figure 3 FJ). All the results indicate that IRG1-mediated ITA promotes the M2 polarization of TAMs and inhibits the phagocytosis of TAMs.
[0099] IRG1-mediated reduction of CD8 by ITA + T cell killing
[0100] To evaluate the function of ITA on cytotoxic T cell killing, CD8 + T cells and co-cultured them with HK-1 cells presenting SIINFEKL using CM from different culture systems. The results showed that incubation with CM from the ITA group did not affect the CD8 + Apoptosis of HK1 cells presenting SIINFEKL in co-culture with T cells was significantly reduced. However, a significant decrease was observed after incubation with CM from the TAM-si-NC group, and this decreased apoptosis rate was reversed after IRG1 knockdown. Importantly, the effect mediated by IRG1 knockdown was overturned after the addition of ITA ( Figure 4 A). In addition, the fluorescence intensity in the cell supernatant of HK-1 cells with luciferase gene in the ITA group did not differ compared with that in the control group. However, the fluorescence intensity in the cell supernatant of HK-1 cells in the TAM-si-NC group was lower compared with that in the control group, but the reduced fluorescence intensity was restored after IRG1 knockdown. Interestingly, supplementation with ITA abolished the effects mediated by IRG1 knockdown ( Figure 4 B) CD8 was also detected +T cells release INF-γ.
[0101] As Figure 4 shown in C, the trend changes in INF-γ concentration in different groups were consistent with the apoptotic status of HK-1 cells and the lysis of HK-1 cells transfected with fluorescent genes. Subsequently, the above results were verified using the NPC cell line HNE2. Figure 4 D-F show that IRG1-mediated ITA inhibits the cytotoxicity of CD8 + T cells against HNE2 cells. These results indicate that IRG1-mediated ita inhibits the cytotoxicity of CD8 + T cells against NPC.
[0102] ITA plays a tumor-promoting role in NPC by mediating immune escape
[0103] After measuring the promoting effect of ITA on the malignant behavior of NPC cells in vitro, this example studied the effect of the combination of ITA and anti-PD-1 antibody on the growth of subcutaneous xenograft tumors in CD34 + humanized mice with hematopoietic stem cells ( Figure 5 A). The results showed that ITA treatment led to a larger tumor volume. In contrast, the administration of anti-PD-L1 antibody had an inhibitory effect on tumor growth. However, the tumors from the ITA + anti-PD-L1 antibody group were smaller than those in the ITA group but larger than those in the anti-PD-1 antibody group ( Figure 5 B and C). Detection of M2-type tams in tumor tissues showed that the ITA group had the highest number of M2-type tams, followed by the ITA + anti-PD-L1 and control groups, which had little difference in the number of M2-type tams.
[0104] As expected, the anti-PD-L1 group had the least number of M2-type tams ( Figure 5 D). The trend in the number of M1-type tams was opposite to the above order ( Figure 5 D). In addition, among the above subgroups, the percentage of CD8 + T-positive in tumor tissues was arranged as follows: ITA < control < ITA + anti-PD-L1 < anti-PDL1 ( Figure 5 E). By administering ITA to BALB / c nude mice, it was further verified whether ITA plays a carcinogenic role through the immune system ( Figure 6 A). The results showed that compared with the control group, the administration of ITA did not cause a significant change in tumor volume ( Figure 6 B and C). These results indicate that ITA plays a carcinogenic role in NPC by promoting tumor immune escape
[0105] ITA plays a tumor immunosuppressive role by binding to and inhibiting TET2 expression
[0106] Considering that ITA can attenuate We then investigated whether TET2 is the target of ITA in NPC carcinogenesis. Based on the fact that TET2 is a DNA demethylase that promotes tumor immunity and improves the efficiency of immunotherapy, we first examined the effects of ITA on M0-type NPC. The dot blot images showed that 5hmC levels were suppressed by ITA in a dose-dependent manner ( Figure 7 A). To investigate whether TET2 mediates the oncogenic effects of ITA, TET2 was knocked down in THP-1 monocytes. A significant decrease in TET2 mRNA and protein levels was observed in THP-1 monocytes after transfection with si-TET2#1, si-TET2#2, or siTET2#3 ( Figure 7 B and C). In addition, ITA promoted M2 TAM polarization, but TET2 knockout inhibited M2 TAM polarization. However, compared with TET2 knockout alone, the combined effect of TET2 knockout and ITA increased M2 TAM polarization, indicating that ITA not only interacts with TET2 but also participates in M2 TAM polarization through other pathways ( Figure 7 D).
[0107] In addition, ITA stimulation increased the M0 The levels of IL-6, IL-10 and VEGF in the TET2-knockout M0 type It is noteworthy that ITA stimulation of HK-1 cells did not affect their M0 phenotype in TET2 knockout cells. The level in Figure 7 EG).
[0108] In addition, we further analyzed whether ITA could interact with TET2 to mediate the phagocytosis of TAMs and CD8 + ITA reduced the phagocytic activity of TAMs, but had little effect on the phagocytic activity of Tet2-knockout TAMs and Tet2-knockout TAMs co-cultured with HK-1 cells stimulated with ITA ( Figure 7 H). In addition, with CD8 + Apoptosis of HK-1 cells co-cultured with T cells was attenuated after incubation with CM from the ITA and si-TET2 groups. In addition, the difference in HK-1 apoptosis between the si-TET2 and si-TET2+ITA groups was not significant ( Figure 7 I). In addition, incubation with CM from ITA and si-TET2 groups reduced CD8 +T cell killing and INF-γ release. However, compared with the si-TET2+ITA group, CD8 + There were no significant changes in T cell killing and INF-γ release ( Figure 7 J and K).
[0109] In general, ITA exerts tumor immunosuppression by interacting with TET2. As the main infiltrating cell subset of TME, the important role of TAMs in tumor progression has attracted great attention. Recently, a variety of immunotherapies targeting TAMs have brought benefits to cancer patients, but they also have certain limitations, such as poor compatibility with other immunotherapies.
[0110] Therefore, exploring the molecular mechanisms associated with TAMs is crucial for developing new immunotherapy strategies for NPC. This study found that TAM-derived ITA weakened CD8 + The killing effect of T cells and the reduction of TAM phagocytosis promote the proliferation, migration and invasion of NPC cells. Figure 8 ).
[0111] Since the function and phenotypic characteristics of tam are closer to M2 type , so tam mainly refers to M2 type Not M1 The recruitment and functional polarization of TME TAMs is an extremely complex process, which is regulated by various cytokines and environmental factors. Tumor cells can recruit circulating monocytes and enhance their ability to polarize to M2 TAMs. metabolites, which promote M2 Polarization plays different roles in different diseases. Ni et al. reported that ITA promotes M2 HK-1 cells can induce M0 phenotype, inhibit ECM degeneration and inflammation in a mouse osteoarthritis model, and thus alleviate osteoarthritis. The M2 type polarization promotes This suggests that HK-1 cells may promote the M2 phenotype by inducing the production of ITA. polarization.
[0112] IRG1-mediated ITA production and accumulation is An important negative regulatory point in inflammation regulation, it inhibits inflammatory responses and regulates disease progression through multiple mechanisms. Recent studies have found that IRG1-induced ITA inhibits the expression and activity of SDH, thereby blocking succinate-mediated inflammatory responses and preventing ROS generated by reverse electron transfer from reducing inflammatory responses. In tumors, the inactivation of SDH and fenugreek hydratase leads to the accumulation of succinate and fenugreek in the cytosol, resulting in the inhibition of the proline hydroxylase family, thereby enhancing tumor cell glycolysis and making cells resistant to apoptotic signals. In addition, targeting IRG1 can reverse TAM-mediated immunosuppression and enhance immunotherapy for cancer. In addition, ITA derived from myeloid cells inhibits CD8 + The cytotoxicity of T cells promoted tumor growth. Here, the addition of ITA attenuated the inhibitory effects of IRG1-knockout TAMs on NPC cell proliferation, migration, and invasion. In addition, after the addition of ITA, IRG1-knockout TAMs inhibited the proliferation, migration, and invasion of CD8 + The promotion of T cell cytotoxicity, as well as the reduction in M2-type TAM polarization and the increase in phagocytosis of IR G1-knockout TAMs were reversed.
[0113] In addition, in CD34 + In hematopoietic stem cell humanized mice, ITA promoted the growth of subcutaneous xenograft tumors and enhanced M2-type TAM polarization, but anti-PD-L1 antibody had the opposite effect. However, after the administration of anti-PD-L1 antibody, the tumor-promoting effect of ITA was weakened. Notably, the administration of ITA in BALB / c nude mice resulted in smaller tumor volume compared with the administration of PBS. These results suggest that ITA plays a tumor-promoting role in NPC by enhancing tumor immune escape.
[0114] TET2 is a member of the TET gene family. TET2 catalyzes the conversion of 5mC in DNA to 5hmC, leading to DNA demethylation. TET2 is a potential tumor suppressor gene that is involved in the epigenetic regulation of methylation or demethylation of early hematopoietic-related genes.
[0115] Mutation or knockout of TET2 leads to the development of several hematological and solid tumors, such as renal cell carcinoma and acute myeloid leukemia. A recent study showed that ITA can interact with TET2 and inhibit TET2 expression by binding to and inhibiting TET2 expression. Here, ITA inhibited the expression of LPS-induced genes in M0 type in a dose-dependent manner. This means that ITA inhibits the expression of TET2. In addition, ITA promotes M2 TAM polarization, inhibits TAM phagocytosis, and reduces CD8 +However, the combination of TET2 knockout and ITA had less effect on the above indicators than the use of ITA, indicating that ITA plays a tumor-promoting role by interacting with TET2.
[0116] In addition, the mechanism by which ITA acts not only through TET2 but also through other targets needs to be further explored.
[0117] In conclusion, TAMs-derived ITAs promote immune evasion and thus NPC progression by interacting with and inhibiting TET2, suggesting that targeting the metabolic pathways that generate ITAs may be a possible approach to interfere with this tumor.
[0118] Abbreviations
[0119] NPC: nasopharyngeal carcinoma; ITA: itaconic acid; TAM: tumor-associated macrophage; : macrophage; IRG1: immune response gene; TET2: Tet methylcytosine dioxygenase 2; TME: tumor microenvironment; CTLs: cytotoxic T lymphocytes; NECs: nasopharyngeal epithelial cells; P / S: penicillin-streptomycin; RT-qPCR: reverse transcription-quantitative PCR; CM: conditioned medium; IFN-γ: interferon-γ; L1: programmed cell death ligand-1; IF: immunofluorescence; ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; SEM: standard error of the mean.
[0120] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.
Claims
1. Application of ITA as a TET2 inhibitor in the preparation of nasopharyngeal carcinoma cell immune escape inhibitors.
2. The use according to claim 1, characterized in that: The specific application is: preparing drugs for reducing the intracellular 5-hydroxymethylcytosine level by inhibiting the demethylation function of TET2, regulating the M2 polarization of TAMs by inhibiting the expression of IRG1 to affect its phagocytic function, inhibiting the killing ability of CD8+T cells on HK-1 and HNE2 cells, and reducing the release of INF-γ.
3. An inhibitor for inhibiting immune escape of nasopharyngeal carcinoma cells, characterized in that: The inhibitor includes itaconate ITA and pharmaceutically acceptable salts thereof which effectively inhibit TET2 activity.
4. The inhibitor according to claim 3, characterized in that: The inhibitor is a substance that inhibits the proliferation, migration and invasion ability of nasopharyngeal carcinoma cells.
5. The inhibitor according to claim 3, characterized in that: The inhibitor has an in vitro action concentration of 125 μM and an in vitro action time of 24 h.
6. The inhibitor according to claim 3, characterized in that: The inhibitor was administered in vivo at a dosage of 50 mg / kg.
